BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22436532)

  • 1. The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study.
    Varughese E; Kondalsamy-Chennakesavan S; Obermair A
    J Ovarian Res; 2012 Mar; 5():11. PubMed ID: 22436532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
    Guo N; Peng Z
    J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care.
    Janke MJ; Santiago S; Straubhar AM; Uppal S
    Int J Gynecol Cancer; 2022 Jul; 32(7):913-917. PubMed ID: 35675968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
    Yoshikawa T; Takano M; Kita T; Kudoh K; Sasaki N; Kato M; Watanabe A; Miyamoto M; Goto T; Furuya K
    Eur J Gynaecol Oncol; 2012; 33(3):269-73. PubMed ID: 22873097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
    Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
    Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
    Abu Hassaan SO
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery.
    Zeng J; Huang H; Shan Y; Li Y; Jin Y; Pan L
    J Cancer; 2017; 8(17):3410-3415. PubMed ID: 29151924
    [No Abstract]   [Full Text] [Related]  

  • 10. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
    Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
    Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
    Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
    Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
    Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma.
    Menczer J; Ben-Shem E; Golan A; Levy T
    Rambam Maimonides Med J; 2015 Jan; 6(1):e0005. PubMed ID: 25717387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.
    Granato T; Midulla C; Longo F; Colaprisca B; Frati L; Anastasi E
    Tumour Biol; 2012 Oct; 33(5):1335-9. PubMed ID: 22528938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the serum CA125 level in recurrent ovarian cancer.
    Nishimura H; Tashiro M; Hamaguchi K; Kiyozuka Y; Ide H; Tateno N; Miyoshi T; Yakushiji M
    Asia Oceania J Obstet Gynaecol; 1992 Mar; 18(1):37-43. PubMed ID: 1320853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.